Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Massachusetts' Agenus Quietly Discloses Failure of Cancer Vaccine Trial February 21, 2017 Cannabis Company GW Pharmaceuticals’ Seizure Drug Flunks Phase II Trial February 21, 2018 Why Secretive $5 Billion Biotech Moderna May Not be Able to Commercialize Products Into Clinical Trials February 13, 2017
Why Secretive $5 Billion Biotech Moderna May Not be Able to Commercialize Products Into Clinical Trials February 13, 2017
